| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigation |
vß3 Expression
1 Department of Nuclear Medicine, Technische Universität München, Munich, Germany; 2 Department of Radiology, Technische Universität München, Munich, Germany; 3 Department of Orthopedic Surgery, Technische Universität München, Munich, Germany; 4 Department of Dermatology, Technische Universität München, Munich, Germany; 5 Department of Gynecology, Technische Universität München, Munich, Germany; and 6 Department of Radiation Therapy, Technische Universität München, Munich, Germany
Correspondence: For correspondence or reprints contact: Ambros J. Beer, Department of Nuclear Medicine, Technische Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany. E-mail: beer{at}roe.med.tum.de
18F-Galacto-RGD is a new tracer for PET imaging of 
vß3, a receptor involved in a variety of pathologic processes including angiogenesis and metastasis. Our aim was to study the dosimetry of 18F-galacto-RGD in humans. Methods: Eighteen patients with various tumors (musculoskeletal tumors [n = 10], melanoma [n = 5], breast cancer [n = 2], or head and neck cancer [n = 1]) were examined. After injection of 133–200 MBq of 18F-galacto-RGD, 3 consecutive emission scans from the thorax to the pelvis were acquired at 6.7 ± 2.9, 35.6 ± 7.6, and 70.4 ± 12.2 min after injection. Blood samples (n = 4) for metabolite analysis were taken 10, 30, and 120 min after injection. The OLINDA 1.0 program was used to estimate the absorbed radiation dose. Results: Reversed-phase high-performance liquid chromatography of serum revealed that more than 95% of tracer was intact up to 120 min after injection. 18F-Galacto-RGD showed rapid clearance from the blood pool and primarily renal excretion. Background activity in lung and muscle tissue was low (percentage injected dose per liter at 71 min after injection, 0.56 ± 0.15 and 0.69 ± 0.25, respectively). The calculated effective dose was 18.7 ± 2.4 µSv/MBq, and the highest absorbed radiation dose was in the bladder wall (0.22 ± 0.03 mGy/MBq). Conclusion: 18F-Galacto-RGD demonstrates high metabolic stability, a favorable biodistribution, and a low radiation dose. Consequently, this tracer can safely be used for noninvasive imaging of molecular processes involving the vß3 integrin and for the planning and monitoring of therapeutic approaches targeting vß3.
Key Words: 18F-Galacto-RGD • vß3 expression • PET • dosimetry • whole-body biodistribution
This article has been cited by other articles:
|
|
 |
|
  Y. Balagurunathan, D. L. Morse, G. Hostetter, V. Shanmugam, P. Stafford, S. Shack, J. Pearson, M. Trissal, M. J. Demeure, D. D. Von Hoff, et al. Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer Mol. Cancer Ther., September 1, 2008; 7(9): 3071 - 3080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Kenny, R. C. Coombes, I. Oulie, K. B. Contractor, M. Miller, T. J. Spinks, B. McParland, P. S. Cohen, A.-M. Hui, C. Palmieri, et al. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients J. Nucl. Med., June 1, 2008; 49(6): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Higuchi, F. M. Bengel, S. Seidl, P. Watzlowik, H. Kessler, R. Hegenloh, S. Reder, S. G. Nekolla, H. J. Wester, and M. Schwaiger Assessment of {alpha}v{beta}3 integrin expression after myocardial infarction by positron emission tomography Cardiovasc Res, May 1, 2008; 78(2): 395 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Hsu and X. Chen Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis J. Nucl. Med., April 1, 2008; 49(4): 511 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Beer, M. Niemeyer, J. Carlsen, M. Sarbia, J. Nahrig, P. Watzlowik, H.-J. Wester, N. Harbeck, and M. Schwaiger Patterns of {alpha}v{beta}3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET J. Nucl. Med., February 1, 2008; 49(2): 255 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Beer, S. Lorenzen, S. Metz, K. Herrmann, P. Watzlowik, H.-J. Wester, C. Peschel, F. Lordick, and M. Schwaiger Comparison of Integrin {alpha}v 3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG J. Nucl. Med., January 1, 2008; 49(1): 22 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Beer, A.-L. Grosu, J. Carlsen, A. Kolk, M. Sarbia, I. Stangier, P. Watzlowik, H.-J. Wester, R. Haubner, and M. Schwaiger [18F]Galacto-RGD Positron Emission Tomography for Imaging of {alpha}v{beta}3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., November 15, 2007; 13(22): 6610 - 6616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wu, Z.-B. Li, K. Chen, W. Cai, L. He, F. T. Chin, F. Li, and X. Chen microPET of Tumor Integrin {alpha}v{beta}3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) J. Nucl. Med., September 1, 2007; 48(9): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Wester Nuclear Imaging Probes: from Bench to Bedside Clin. Cancer Res., June 15, 2007; 13(12): 3470 - 3481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Feng and A. Eisbruch Future Issues in Highly Conformal Radiotherapy for Head and Neck Cancer J. Clin. Oncol., March 10, 2007; 25(8): 1009 - 1013. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
